Quintiles Names COO And CFO
This article was originally published in Scrip
Quintiles, a provider of product development and integrated healthcare services, has promoted Kevin Gordon from executive vice-president of operations and chief financial officer (CFO) to chief operating officer (COO). In parallel the company has appointed Michael McDonnell executive vice-president and CFO. McDonnell is expected to join the company in December 2015, until then Gordon will continue to serve as CFO. Gordon joined the company in 2010 and led Quintiles' capital strategy including its 2013 initial public offering. McDonnell will join Quintiles from Intelsat where he was CFO and he has previously held the same position at MCG, a publicly held commercial finance company, and EchoStar Communications, formerly known as DISH Network Corporation.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.